Parathyroid carcinoma (PC) is a rare endocrine malignancy and the cause of primary hyperparathyroidism. It is usually associated with a high rate of local and distant recurrence. Laboratory findings and clinical symptoms may be similar to those in parathyroid adenoma. The histological features of PC may also be non-specific and the affected gland is often indistinguishable from a benign lesion. The proper diagnosis is commonly made months to years later when the disease recurs or metastases are present. Therefore, parathyroid carcinoma still remains a diagnostic and management challenge for many physicians. However, there are some features that, in combination, may help in diagnosis. Surgery still remains the only curative treatment, even in metastatic disease. In advanced, non-operable subjects, managing hypercalcaemia and controlling a tumour are the main goals. Morbidity is caused by hypercalcaemia rather than metastases. A multidisciplinary approach with experienced endocrinologists, pathologists, radiologists, nuclear medicine doctors, oncologists, and surgeons is needed to optimize patient outcome. 
Introduction
Parathyroid carcinoma (PC) was first described by De Quervain in 1904 [1, 2] . It is a rare endocrine malignancy [3] [4] [5] [6] , which originates in the parenchymatous cells of the parathyroid glands [1] . Most parathyroid cancers secrete PTH and cause hypercalcaemia in the course of primary hyperparathyroidism [7, 8] . Only a small fraction of PCs (up to 10%) are non-functional, and this group of neoplasms is associated with poorer prognosis due to local invasion and distant metastases, usually present at the time of diagnosis [8] [9] [10] .
The affected gland is often indistinguishable from a benign atypical adenoma and the proper diagnosis is made months to years later when the disease recurs or metastases are present [8] . What is more, PC may be present in patients with parathyroid adenomas or hyperplasia [11] . Double (multi-glandular) parathyroid carcinoma is rare [12] . The histological features of PC may initially be also non-specific [3, 4] . Moreover, parathyroid gland could be located in ectopic sites such as the mediastinum, the base of the skull, and within the thyroid gland, and when it occurs the diagnostic difficulty increases significantly [2, 13] . It is known
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that a delay in diagnosis deteriorates the prognosis, and morbidity is caused by hypercalcaemia rather than metastases [11, 14] . Due to a rarity of PC, there is still a lack of understanding of the natural course and prognostic implications of the disease. Therefore the consensus regarding its management and follow-up is not clear [10] .
Epidemiology of parathyroid carcinoma
According to the National Cancer Database, parathyroid carcinoma is the least common endocrine malignancy and constitutes 0.005% of all cancers [8, 15] . The prevalence of PC is estimated to be less than 1% of cases of primary hyperparathyroidism, and incidence from 3.5 to 5.73 per 10 million has been reported [3] [4] [5] [6] . However, in Japan and in Italy this cancer is more prevalent compared to other Western countries, concerning about 5% of subjects with hyperparathyroidism [9, 16, 17] . It is unclear whether the discrepancy of incidence rate reflects ethnic differences or varying diagnostic criteria [17] .
The sex ratio of PC is close to 1 and the mean age of onset is 45-55 years, which differentiates it from parathyroid adenoma occurring predominantly in postmenopausal women [18] [19] [20] [21] .
Aetiology of parathyroid cancer
The aetiology of parathyroid cancer is not clear but the role of genetic and environmental factors, e.g. irradiation has been proposed [7, 8, [14] [15] [16] . The genes, which may be involved in the pathogenesis of PC, are suppressor genes and their products act in the function of cell cycle regulators. This group of genes include: retinoblastoma gene (Rb), p53 gene, breast carcinoma susceptibility (BRCA2), and cyclin D1/parathyroid adenomatosis gene 1 (CD1/PRAD1) [9, 14, 18] . In cases of PC, somatic loss of DNA at Rb locus with decreased immunohistochemical staining of RB protein and allelic loss of p53 with abnormal p53 protein expression have been found. Overexpression of CD1 occurs at least in 18% of cases with PCs [9] . It is also known that somatic and germinal mutations of the HRPT2/CDC73 tumour suppressor gene (hyperparathyroidism 2 gene), encoding parafibromin (CDC73), are associated with inherited primitive hyperparathyroidism with mandible and maxilla tumours (HPT-JT, Hyperparathyroidism-Jaw Tumour Syndrome), and these mutations are demonstrated in a high percentage of PC cases [8, 19, 22] . Parafibromin is a member of the polymerase-associated factor 1 (PAF1) complex connected with RNA polymerase II, which regulates transcription, elongation, and histone modification [23] . On the one hand, some studies indicate that 10-15% of parathyroid adenomas in patients with HPT-JT progress to cancer. On the other hand, somatic gene mutations of HRPT2/CDC73 are present in 66-100% of sporadic parathyroid carcinomas and occur sparsely in adenomas [17, [23] [24] [25] . Moreover, Svedlund et al. [26] reported that EZH2 gene amplification (an oncogene, the histone 3 lysine 27 methyltransferase) is a genetic aberration common to parathyroid tumours.
Besides the genes that are overexpressed in parathyroid carcinoma (compared to normal parathyroid tissue), many genes are downregulated, such as: PTH (parathyroid hormone gene), VDR (vitamin D receptor gene), CHG A (chromogranin A gene), OGN (osteoglycin gene), and ESRRG (oestrogen-receptor related gamma gene) [17] .
Parathyroid cancer may be an isolated disease or integral part of multiple endocrine neoplasia type 1 (MEN 1) or type 2A (MEN 2A) [7, 8] . MEN 1 syndrome is associated with germline MEN1 tumour suppressor gene mutation and includes the combination of neoplasms located most commonly in the parathyroid glands, the anterior pituitary gland, and the pancreas [24, 27] . In the classic forms of MEN 1, hyperparathyroidism is usually the earliest clinical presentation [28] . MEN 2A syndrome is caused by germline RET proto-oncogene mutation and is composed of medullary thyroid cancer, pheochromocytoma, and parathyroid tumour [29] .
However, changes in expression of some genes are not only characteristic for PCs, but they are also present in 20-40% of adenomas and 50% of hyperplasia [1, 26] .
Some authors suggest that prolonged secondary hyperparathyroidism due to celiac disease or accompanying end-renal disease with haemodialysis or hyperplastic parathyroid gland are predisposing factors for PC [10, 17, 30] .
Laboratory findings and clinical symptoms of primary hyperparathyroidism
Diagnosis of primary hyperparathyroidism is based on elevated serum calcium and ionised calcium levels and hypophosphataemia in combination with increased urinary calcium excretion in the presence of normal or more commonly elevated PTH concentration [7, 19, 31] . Systemic symptoms of hypercalcaemia include: fatigue, weakness, weight loss, anorexia, nausea, vomiting, polyuria, polydipsia, and depression. Patients with primary hyperparathyroidism suffer from increased loss of cortical bone, but their trabecular bone is less affected [32] . Bone disease is usually presented as: osteitis fibrosa cystica, subperiostial bone resorption, "salt and pepper" skull, absence of the lamina dura, diffuse osteopaenia, and osteoporosis, which may lead to pathological fractures and bone pain. Brown
PRACE POGLĄDOWE
tumours, usually localized in the jaws, the pelvic bones, the sternum, and the plate, are focal lesions found within areas of bone resorption. They are made up of mononuclear stromal cells mixed with multinucleated giant cells with haemorrhagic infiltrates and haemosiderin deposits [33] . Renal complications are manifested by: nephrolithiasis, nephrocalcinosis, renal colic, and in some cases by renal impairment. Moreover, other symptoms such as: anaemia, peptic ulcer disease, and pancreatitis may appear and complicate the picture [8, 9, 31] . The presence of a paralysed recurrent laryngeal nerve is a rare physical finding and indicates advanced and invasive disease [10] .
Extremely elevated concentrations of calcium in the serum (> 14 mg/dL) due to excessive production of PTH may cause life-threatening hypercalcaemic parathyroid crisis, which leads to cardiac and renal disturbances, nausea, vomiting, lethargy, confusion, stupor, and coma [5, 7, 34] . It is estimated that hypercalcaemic crisis, termed also as parathyrotoxicosis, acute hyperparathyroidism, parathyroid storm, parathyroid intoxication, or poisoning, occurs in 7-12% of patients with PC [10, 35] . Despite advances in the management of hypercalcaemic crisis, the mortality is high and may reach almost 16% [35] .
The natural course of parathyroid carcinoma
The disease typically follows one of three courses: one third of patients are cured at initial or follow-up surgery, one third experience a recurrence after a prolonged disease-free survival but may be cured with re-operation, and one third have a short and aggressive course [9] . In patients with parathyroid cancer, metastases occur late and spread by both lymphatic and haematogenous routes [12, 16] . Data indicate that about 25% of subjects develop distant metastases but they are rarely present at the time of diagnosis [8] . The most frequent sites of metastases are: regional lymph nodes (30-40%), the lungs (20-40%), the liver (10%), and more rarely the bones and the brain [5, 9, 18] .
Parathyroid malignancy is usually associated with a high rate of local and distant recurrence, despite curative resection, and most of patients require re-operation [3, 4, 25, 36] . Persistent hypercalcaemia and progressive increase in PTH levels are often the first signs of recurrence [1, 18] . The average time to the first recurrence is approximately three years, and if is shorter than two years, it is associated with poorer prognosis, but intervals of up to 20 years have been reported as well [8, 9, 14] . It has also been described that from 40% to as much as 57% of patients with PC had at least one recurrence over a 5-to 10-year period [15] . Initially en bloc resection decreases the percentage of recurrences, and then the recurrence rate is estimated to be about 33% [25, 37] .
Localizing examination of parathyroid cancer
Parathyroid lesions may be localized by non-invasive or invasive methods. Non-invasive examinations include: ultrasound diagnostics (US), computerised tomography (CT), and magnetic resonance imaging (MRI). Invasive methods are: fine-needle aspiration biopsy (FNA), arteriography, and selective vein catheterisation [7, 38] .
It is known that PTH concentrations are high in aspirates from the parathyroid gland and they are often greater than 46.31 pg/mL [39] . Measurements of PTH levels in aspirate, obtained during FNA, may be useful to determine whether sonographically detected suspected lesions originate from parathyroid tissue [13] . Kiblut et al. [40] reported that a level of PTH greater than 1000 pg/mL is strongly predictive of a pathological parathyroid gland, with a sensitivity reaching 87%. Abdelghani et al. [41] found that FNA washouts are positive when the result is higher than serum PTH level, but Maser et al. [42] reported that it should be higher than the normal range in an applied assay. However, the reference range has not been established yet. Popowicz et al. [43] emphasise that the limit depends on whether the PTH-FNA concentration is determined in the diluted material or directly. They also found that PTH measurements in aspirates, obtained during FNA, show a significant advantage for establishing the parathyroid origin in relation to classical cytological examination. This method is especially useful when aspirated material is scarce or is contaminated within thyroid follicular cells from the needle tract.
Large size, inhomogeneous appearance, irregular borders, and a depth width (DW) ratio ≥ 1 are ultrasonographic but nonspecific features of PC [17] . Local infiltration, calcification, suspicious vascularity, and the presence of a thick capsule may also be predictive factors of malignancy [10] .
According to the fact that more than 90% of parathyroid cancers are functional, Tc-99m-MIBI scintigraphy (99mTc-hexakis2-methoxyisobutylisonitrile scintigraphy) may be a useful tool to localize the primary lesion and sites of recurrence or metastases [4, 17, 25] . The radioisotope is taken up by the diseased parathyroid rapidly and retained longer [2] . However, some patients with PC may have negative scans [39] . Moreover, 18 F-FDG PET/CT ( 18 F-fluorodeoxyglucose positron emission tomography/computed tomography) is a helpful method for detecting the cancer and the presence of metastases [5, 12, 25] . Additionally, SPECT/CT (singlephoton emission computed tomography/ computed PRACE POGLĄDOWE tomography) may be a useful technique because allows a direct correlation between anatomic and functional information [5] . If recurrent parathyroid cancer is suspected, neck and chest CT or MRI scans should be performed [6, 20, 21] .
Histopathological examination
It is very difficult to distinguish parathyroid cancer from parathyroid adenoma based on histopathological criteria [4, 44] . Fine needle aspiration biopsy (FNA) is not reliable because of common false-negative results, and if it is performed, it should be used with caution due to the risk of rupturing the capsule and consequent seeding of tumour cells (parathyromatosis) [6, 13, 16] . However, FNA may occasionally be utilised in the setting of suspected metastatic disease or in cases of recurrence, with the purpose of confirming the diagnosis prior to more radical surgical interventions [10] .
It has been reported that sensitivity for FNA in diagnosing malignancy is about 50% [2] . In 1973 Schantz and Castleman proposed the criteria that may be helpful to diagnose cancer. They contain: increased mitotic activity, thick fibrous bands, trabecular growth pattern, and capsular and blood vessels invasion (present in over 60% of cases) [15, 18, 45] . Unfortunately, none of these criteria are specific only for parathyroid carcinoma; they can also be observed in benign parathyroid lesions and are not always present in cases of malignancy [5, 6, 18] . In particular, oxyphil adenoma can mimic PC because both are rich in oxyphil cells, contrary to typical adenoma, which is formed from chief cells [6] . Some authors suggested that cellular atypia, including nuclear enlargement, pleomorphism, and macronucleoli are connected with a greater likelihood of malignancy [9, 16] . It is also known that more aggressive clinical behaviour of parathyroid cancer is associated with the presence of the triad of histological features, which includes presence of coagulation necrosis, large nucleoli, and more than five mitotic figures per ten high-power fields [18] .
Immunohistochemistry analysis may be a useful technique in diagnosing parathyroid carcinoma. A decreased or absent nuclear expression of parafibromin is a sensitive and specific marker for parathyroid malignancy (67-96% and 99-100%, respectively) [18, [46] [47] [48] . By contrast, 98-100% of sporadic adenomas stain completely positive for parafibromin. However, a negative staining is not automatically consistent with parathyroid carcinoma and cannot be used alone as a diagnostic marker [23] . The sensitivity is higher when positive staining of PGP9.5 (encoded by ubiquitin gene UCHL1), combined with loss of parafibromin, is found [18, 19, 46] . What is more, loss of retinoblastoma protein is an additional reliable factor for making the proper diagnosis [3, 8, 36] . Overexpression of galectin-3 is also present in PCs [8] .
Moreover, it has been reported that a higher than 10% Ki-67 proliferation index is associated with a risk of parathyroid carcinoma and possibility of recurrence, even after radical surgical resection [1, 8, 18] . Cyclin D1 is another proliferation marker that also demonstrates higher expression in carcinomas than in adenomas [9] .
Gawrychowski et al. [47] suggested the usefulness of cytofluorometry in distinguishing between benign parathyroid lesions and cancers. Aneuploidy is thought to be predictive for malignant conditions and if present, is associated with poorer prognosis in patients with parathyroid carcinoma [9, 15, 16] .
The histopathological features that may be helpful in diagnosing parathyroid carcinoma have been collected in Figure 1 .
Making the diagnosis of parathyroid carcinoma
Although histopathological features, clinical manifestations, and laboratory findings are usually non-specific for parathyroid cancer, there are some factors that can indicate the presence of malignant tumour [5, 6] . What is more, the combination of them may help in making the proper diagnosis [5, 18, 47] . The typical histopathological features for PC are discussed above.
Most patients with parathyroid cancer are symptomatic at the time of diagnosis, in contrast to patients with adenomas [25, 44] . They often present with more severe signs and symptoms of hypercalcaemia [16, 49] .
Extremely high PTH (> 5 times normal or > 500 pg/mL and often > 1000 pg/mL) and calcium (> 14 mg/dL) concentrations may be the first signs of malignancy. Data suggested that about 5% of subjects with hyperparathyroid crisis suffered from parathyroid cancer [34] . Additionally, patients with PC had 30 to 60% incidence of severe hypercalcaemia [6, 25, 36] . Patients with PC also have a greater chance of persistent or recurrent hyperparathyroidism than subjects with adenomas or hyperplasia [11] . Bae et al. [14] , based on their study of 194 subjects with primary hyperparathyroidism, suggested that the serum level of alkaline phosphatase may be helpful to predict parathyroid cancer before operation. In their study, the concentration of alkaline phosphatase was higher in patients with cancer compared to subjects with adenomas, and the participants who had level greater than 300 IU/L were likely to have parathyroid carcinoma. What is more, serum alkaline phosphatase can reflect the effect of PTH on the bones earlier than bone mineral density and fractures [14, 17] . Moreover, some authors described that patients with
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PC may have elevated levels of a-and b-subunits of hCG [8, 16] .
The classical target organs for PTH -the kidneys and the bones -are usually affected with greater frequency and severity in cancer than in parathyroid adenoma [16] . Nephrolithiasis or nephrocalcinosis (in 30-60% of cases), renal insufficiency, bone pain, pathological fractures, and radiological findings such as osteitis fibrosa cystica (in 40-70% of cases), "salt and pepper" skull, and diffuse spinal osteopenia, are more common in PC. Similarly, severe pancreatitis and peptic ulcer disease occur more often in subjects with malignant disease [36, 50, 51] . Some authors reported that a palpable mass in the neck might be a helpful predictive factor for parathyroid carcinoma, but it is present in 15 to 75% of cases [11, 18, 52] . Other important clinical features suggesting parathyroid malignancy include: known distant metastases, hoarseness and recurrent laryngeal paralysis, or palpable cervical swelling (in 30-50% of cases) [36, 50, 51] .
However, some patients with benign tumours present with more severe symptoms of primary hyperparathyroidism than those with malignancy [11, 24, 49] . Therefore, it is sometimes extremely difficult to distinguish parathyroid adenoma from parathyroid cancer and it is not possible to diagnose PC before operation [5, 14, 16] .
There are some features that are useful in making diagnosis during surgery. It has been thought that lesions larger than 3 cm and a tumour weight excess of 2.5 g are strong indicators of malignancy [9, 14, 53] . Besides these features, multi-nodular surface, solid consistency, and infiltration of surrounding tissues (ipsilateral thyroid lobe, cervical muscles, vessels, lymph nodes) may help in the differential diagnosis [16, 54, 55] . Invasion normally affects the thyroid gland (15%) and regional lymph nodes (4%) [21, 45, [50] [51] [52] [53] [54] [55] [56] . In contrast to carcinoma, parathyroid adenoma tends to be smaller, soft, and ovoid with a brown colour and yellowish undertones [6, 20] (Table I) .
Surgical treatment
The TNM staging for parathyroid cancer has not been clearly defined yet [10] . Surgery still remains the only curative treatment, even in metastatic disease [2, 3, 5] . En bloc resection of the tumour with ipsilateral thyroid lobectomy, adjacent musculature, paratracheal lymphatic tissue (level VI), and sometimes thymus is often recommended for parathyroid carcinoma; however, it is possible only in 10 to 15% of cases because of delay in diagnosis and advanced disease [4, 6, 14] . Before surgery, every patient with primary hyperparathyroidism should be evaluated against algorithms elucidating the risk of cancer [57] . Primary oncologic en bloc resection has a survival advantage and is associated with lower recurrence rates than simple parathyroidectomy [17, 57] . A successful operation is confirmed by a noticeable, at least > 50% from baseline, decrease in PTH level. Drop in intraoperative PTH concentrations may predict at least six months of postoperative normocalcaemia • Symptomatic disease at the time of diagnosis (asymptomatic < 5%)
• Markedly elevated PTH level (> 5 times normal or > 500 mg/mL
• High serum calcium level (> 14 mg/dL)
• High serum alkaline phosphatase concentration (300 IU/L)
• Elevated levels of a-and b-subunits of hCG
• Renal involvement (nephrolithiasis, nephrocalcinosis, renal insufficiency)
• Skeletal involvement (bone pain and pathological fractures, osteitis fibrosa cystica, diffuse osteopenia, "salt and pepper" skull on radiographs)
• Severe pancreatitis or peptic ulcer disease PRACE POGLĄDOWE [13, 24, 47] . If the diagnosis of PC is made after surgery, re-exploration of the neck with resection of tissues contiguous to the tumour should be performed [16] . Special care must be taken to avoid disruption of the tumour capsule during operation to prevent seeding of the cancer cells [6, 11, 16] . In cases of recurrence, ipsilateral laryngeal, jugular, and carotid lymph nodes as well as pretracheal adipose tissue should be removed [18, 24] . Surgery is also a recommended therapy in subjects with metastatic disease, especially when single metastases occur [1, 5, 9] . Even though the operation is only palliative, it should be performed because improvement of hypercalcaemia and relief of its symptoms may be achieved [8, 9, 16] . Surgery complications include: recurrent laryngeal nerve injury, transient or permanent hypoparathyroidism, oesophageal or tracheal injury, and neck haematoma [8, 58] . "Hungry bone syndrome" is expected to occur in patients with severe bone disease; therefore, postoperative levels of calcium should be monitored [6, 58] . It is caused by substantial decrease in serum PTH level, which induces cessation of osteoclastic bone resorption without affecting osteoblastic activity. Increased bone uptake of calcium, phosphate, and magnesium are observed. Risk factors for "hungry bone syndrome" include: large parathyroid tumour, age > 60 years, and high preoperative PTH, calcium, and alkaline phosphatase levels [9, 17] . Those patients usually require initially large doses of calcium i.v. followed by sufficient oral calcium supplementation and gradual reduction of calcium doses and calcitriol supplementation, based on calcium and PTH concentrations [9, 16, 17] .
Non-surgical treatment strategies
In advanced, non-operable subjects, managing hypercalcaemia and controlling the tumour are the main goals [3, 6, 16] .
Medical treatment of hypercalcaemia, including hypercalcaemic crisis

Vigorous hydration/rehydration
Conventional treatment, including fluid infusion (isotonic saline) and loop diuretics, is used because aggressive hydration and furosemide administration increase the renal excretion of calcium, but the effect is usually short-term [15, 25, 59] .
This method of treatment requires the infusion of large quantities of 0.9% saline, frequently 3-6 L over the first 24 hours. If there is a danger of salt and water retention, a loop diuretic may be added [35, 60] . This is the only role of diuretics in the management of hypercalcaemia and is not a routine practice, contrary to previous historical texts. Loop diuretics can precipitate intravascular volume depletion and worsening hypercalcaemia [60] .
Bone resorption inhibitors:
Bisphosphonates Bisphosphonates are a group of drugs that inhibit osteoclast-mediated bone resorption [35] . Pamidronate and zoledronate are the most potent [9, 16, 39] . Oral bisphosphonates are ineffective in PC because of poor absorption, so they should be given intravenously [59] . These drugs lower calcium levels without influencing the tumour progression and provide short-term control of the symptoms of severe hypercalcaemia [1, 5, 39] . The dosage of pamidronate ranges from 60 mg to 90 mg (given over 2-4 hours), and the response lasts for 1-3 weeks. Zoledronate may be administered more rapidly: 4 mg over 15 minutes [25, 39, 61] . In patients with kidney disease, bisphosphonates can worsen renal function and may cause acute renal impairment [25] .
Calcitonin
Calcitonin is a drug that inhibits osteoclast-mediated bone resorption and increases urinary calcium excretion [16, 39] . It is administered subcutaneously or intramuscularly at a dose of 3-6 IU/kg [25] . In combination with glucocorticoids, even in subjects with renal failure, calcitonin may be useful in acute hypercalcaemia [59] . However, its effect on the calcium concentration is transient and lasts 12 to 24 hours [5, 25, 62] . Calcitonin also has no impact on disease progression [5] . Nowadays calcitonin is rarely used in the acute management of hypercalcaemia.
Mithramycin
Mithramycin is an antibiotic with cytotoxic activity that inhibits RNA synthesis in osteoclasts [62] . It is given intravenously at one dose of 25 µg/kg and lowers calcium concentrations in the 12 hours after administration [63] . However, the effect of mithramycin on calcium levels is insufficient and transient (it lasts from a few days to several weeks). Moreover, this therapy may cause severe side effects, such as: neuro-, nephro-, myelo-, and hepatotoxicity [62, 63] .
Gallium nitrate
Gallium nitrate inhibits PTH secretion from parathyroid cells in vitro. It also inhibits osteoclastic bone resorption [61] [62] [63] [64] . It may lower calcium levels in some patients. Gallium nitrate is administrated intravenously at a dose of 100-200 mg/m 2 /24 hours, over 5 days. However, neurotoxicity can limit its use in therapy [63] .
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Corticosteroids
Corticosteroids can be also used in managing hypercalcaemia [39] . Hydrocortisone lowers calcium levels by increasing its urinary excretion and decreasing its intestinal absorption. It is usually given intravenously at a dose of 200-300 mg daily. Unfortunately, the onset of corticosteroids action ranges from days to weeks and they have side effects such as hyperglycaemia, immunosuppression, and Cushingoid symptoms [25] .
Nowadays glucocorticoids are rarely used in the acute management of hypercalcaemia. Treatment with high-doses of glucocorticoids is recommended to control granulomatous disorders (sarcoidosis) activity and to minimise the gastrointestinal effects of the excess of 1,25(OH)D3. Sometimes they are used in cases of vitamin D intoxication [60] .
Haemodialysis
Some subjects with parathyroid carcinoma require haemodialysis. This therapy can be considered for calcium levels over 18 mg/dL with neurological symptoms and a stable circulation [61] .
Drugs registered for the treatment of hypercalcaemia due to PC
Cinacalcet Cinacalcet belongs to second-generation calcimimetics, which fix onto the calcium receptor on the membrane of parathyroid cells and thus reduce PTH secretion and additionally increase the receptor's sensitivity to extracellular calcium [1, 5, 9] . It is administered orally and is well tolerated, even in doses up to 360 mg [8, 25] . The most common adverse effects of cinacalcet are: nausea, vomiting, dehydration, and headache, but patients with PC can tolerate higher doses than those with parathyroid adenoma [17, 59] .
Silverberg et al. [59] reported the efficacy of cinacalcet (maximal dose 90 mg four times daily) in 29 patients with parathyroid cancer. In this study 62% of subjects responded to therapy, and a decrease in calcium levels in the serum was achieved. The greatest reduction was observed in subjects with the highest baseline calcium level (≥ 14.3 mg/dL).
The extra benefit of cinacalcet is the possibility of using it in patients with renal insufficiency, which often occurs in those subjects. The drug has been also approved for use in patients on dialysis [59] .
The effect of cinacalcet on tumour growth in humans is not yet known. In animal models of secondary hyperparathyroidism, calcimimetics attenuated parathyroid gland cell proliferation, partially due to increased expression of the endogenous cyclin-dependent kinase inhibitor p21 [65] .
Chemotherapy
Chemotherapy has demonstrated variable and disappointing results in patients with PC [6, 15, 16] . It is known that many subjects respond poorly to chemotherapy [1, 5, 56] . However, the response in the serum calcium and distant metastases after using cyclophosphamide, 5-fluorouracil, and dacarbazine has been reported [3, 9] . A good efficacy of single dacarbazine, MACC regimen (methotrexate/adriamycin/cyclophosphamide/cyclonexyl-chloroethyl-nitrosourea) and synthetic oestrogen therapy has also been described [9, 16, 25] . No survival benefit after using chemotherapy has been found [15, 62] .
Radiotherapy
The efficacy of radiotherapy remains controversial [24, 36, 66] . On the one hand, it is known that parathyroid cancer metastases are not radiosensitive [5, 16, 56] . On the other hand, results from recent studies at Princess Margaret Hospital in Toronto, the Mayo Clinic, and the University of Texas M.D. Anderson Cancer Centre indicate that postoperative adjuvant radiation therapy may prevent locoregional disease progression, increase disease-free interval, or improve long-term survival [15, 25, 34] . The standards and the criteria for radiotherapy in subjects with PC as well as the total dose have not been clearly defined yet [62] .
Experimental strategies
Anti-PTH immunotherapy
Immunisation with synthetic human and bovine PTH peptides resulted in production of anti-PTH antibodies [8, 9] . Decrease in hypercalcaemia and improvement in clinical symptoms after immunisation by administration the bioactive section of PTH have been reported [9, 16, 67] . No significant side effects have been observed [16] . It has been suggested that autoantibodies against parathyroid hormone prevented the binding PTH to its receptors and resulted in lowering of calcium concentrations in the serum. Anti-PTH immunotherapy can control tumour growth, reduce the calcium and PTH level, and improve the patient's physical status [5, 8, 56] . Unfortunately, tumour regression has not been achieved [5, 56, 67] . Up to this day, only a few cases have been treated with anti-PTH immunotherapy and further investigations and follow-up are needed to use this method commonly [5, 22] .
Zidovudyne
An in vitro study on human parathyroid cancer cells showed that the anti-retroviral agent zidovudyne could be a potential therapeutic target in patients with parathyroid carcinoma [68] . It is known that zidovudyne
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inhibits telomerase, an enzyme that is active in parathyroid cancer cells. Falchetti et al. [68] demonstrated that zidovudine accumulates in malignant parathyroid cells and thus induces their apoptosis. However, additional studies are required to confirm these findings in humans.
Denosumab
Denosumab, a monoclonal antibody with anti-resorptive actions in bone, has been tested for controlling hypercalcaemia in PC [15] . It blocks the receptor activator of nuclear factor kappa B (RANK) ligand and inhibits osteoclast activation [69] .
Bowyer et al. [3] reported rapid suppression of bone turnover (monitored by urinary N-telopeptide levels) and decrease in calcium and creatinine levels after denosumab therapy. Two loading doses of 120 mg of denosumab have been used. However, despite control of hypercalcaemia, parathyroid cancer progressed [3] .
Vellanki et al. [64] described successful denosumab therapy in a patient with refractory hypercalcaemia in PC, who initially responded to surgery, bisphosphonates, calcium receptor agonist, and chemotherapy (dacarbazine).
Percutaneous vertebroplasty (PVP)
Spinal surgical procedures are invasive and the risk of complications is high [5] . PVP may be a good alternative to treat the osteolytic destruction. It is a minimally invasive radiological-guided procedure in which bone cement (polymethylmethacrylate) is injected into structurally weakened vertebra. It provides not only long-term biomechanical bone stabilisation but also relief from pain [5] . Moreover, Qiu et al. [5] reported that PVP affected normalisation of PTH levels and prevented compression fractures and bone destruction in subjects with bone metastatic disease.
Other experimental therapies
Sharretts et al. [8] reported using sessions of radiofrequency ablation (RFA) to treat diffuse metastases in the lung and in the liver. They also described a short-term improvement in calcium and PTH concentrations after ultrasound-guided percutaneous alcohol injection into the lesion, in patients with recurrent disease in the neck [8] .
The long-acting somatostatin analogue octreotide has also been reported to inhibit PTH secretion in a woman with PC metastatic to bone [16] .
Prognosis
Parathyroid carcinoma is slow growing, but the clinical course depends on the aggressiveness of the individual tumour and the degree of hypercalcaemia [9, 25] . The prognosis of parathyroid carcinoma is also closely linked to local disease extension at the time of diagnosis, surgical radicality at the first intervention, and the possibility of local relapse within the first two years of the treatment [1, 6, 19] . Subjects with local recurrence or metastatic disease have poorer prognosis [9, 25] . En bloc resection significantly improves long-term survival [25, 36, 66] . Erovic et al. [36] described that angioinvasion and positive resection margins were critical factors regarding disease-free survival in the patients with parathyroid carcinomas. Tumour size and lymph node status have no impact on prognosis [6, 9, 15] . Male sex, young age, and higher calcium levels are adverse clinical prognostic factors for patients with parathyroid carcinoma [4, 15] . Greater than 10% Ki-67 index may be a valuable prognostic indicator for recurrence in the early postoperative period [9] . Morbidity is caused by complications of severe persistent hypercalcaemia such as cardiac arrhythmias, renal failure, pathological fractures and neuropsychiatric symptoms rather than direct tumour invasion or metastases [1, 5, 6, 8] .
The National Cancer Database survey reported a 5-year survival rate of 86% and a 10-year survival rate of 49% [16, 25, 30] . The MD Anderson Cancer Centre indicated longer 10-year survival, which reached for 77% [5, 15] . 28-50% of patients after en bloc resection remained alive with no recurrences [8] . The 5-year survival rate after recurrent disease is approximately 50% [59] .
In patients with parathyroid carcinoma long-term follow-up is recommended because recurrence can happen up to 20 years after surgery. Close follow-up is required during the first two years from initial treatment due to a higher rate of recurrence during this period [17] .
Conclusions
The low prevalence of parathyroid cancer and the lack of typical symptoms and histological features usually cause delay in diagnosis that deteriorates prognosis. Additionally, parathyroid carcinoma is usually associated with a high rate of local and distant recurrence, despite curative resection. Therefore, parathyroid carcinoma still remains a diagnostic and management challenge for many physicians. Parathyroid cancers should be evaluated by experienced endocrinologists, pathologists, radiologists, nuclear medicine doctors, oncologists, and surgeons. A multidisciplinary approach is needed to optimize patient outcome.
PRACE POGLĄDOWE
u pacjentów z rakiem w porównaniu z chorymi z gruczolakiem, a najbardziej prognostyczne było stę-żenie przekraczające 300 IU/l [14] . Co więcej, stężenie fosfatazy zasadowej w surowicy może odzwierciedlać wpływ PTH na kości dużo wcześniej, niż gęstość mineralna kości lub wystąpienie patologicznych złamań [14, 17] . Ponadto według niektórych autorów, u pacjentów z rakiem przytarczyc stwierdza się podwyższone stę-żenia podjednostek a-i b-hCG [8, 16] .
Typowe organy docelowe dla PTH -nerki i kości -są zwykle zajmowane najczęściej, a zmiany chorobowe mają bardziej zaawansowany charakter w przypadku raka przytarczyc niż gruczolaka [16] . W raku przytarczyc częściej obserwuje się kamicę lub wapnicę nerkową (w 30-60% przypadków), niewydolność nerek, bóle kostne, złamania patologiczne oraz zmiany radiologiczne, takie jak osteitis fibrosa cystica (w 40-70% przypadków), zmiany typu ,,sól i pieprz" w kościach czaszki oraz rozsianą osteopenię w kręgosłupie. Podobnie jak ciężkie zapalenie trzustki, również choroba wrzodowa częściej występuje u osób z rakiem przytarczyc [36, 50, 51] . Niektórzy autorzy twierdzą, że typowym objawem raka przytarczyc jest obecność wyczuwalnego palpacyjnie guza na szyi, którego występowanie waha się w granicach 15-75% przypadków [11, 18, 52] . Innymi znaczącymi klinicznie cechami, sugerującymi obecność raka, są: przerzuty odległe, chrypka i porażenie nerwu krtaniowego wstecznego lub obrzęk tkanek szyi (w 30-50% przypadków) [36, 50, 51] .
Zdarza się jednak, że u części pacjentów z guzami łagodnymi objawy kliniczne pierwotnej nadczynności przytarczyc są bardziej nasilone, niż u osób z rakiem przytarczyc [11, 24, 49] . Dlatego też czasem niezwykle trudno jest odróżnić gruczolaka od raka przytarczyc, a postawienie ostatecznej diagnozy możliwe jest dopiero po zabiegu operacyjnym [5, 14, 16] .
Istnieją jednak pewne cechy kliniczne, które mogą być przydatne w przedoperacyjnej diagnostyce róż-nicowej raka przytarczyc. Najbardziej podejrzane o złośliwy charakter są zmiany większe niż 3 cm, ważące ponad 2,5 g [9, 14, 53] . Poza tym, pomocne w diagnostyce różnicowej mogą być następujące cechy: wieloguzkowa struktura, lita konsystencja oraz naciekanie otaczających tkanek (płat tarczycy po tej samej stronie, mięśnie szyi, naczynia, węzły chłonne) [16, 54, 55] . Naciekanie tkanki tarczycowej stwierdza się w 15% przypadków, a zajęcie regionalnych węzłów chłon-nych w 4% [21, 45, [50] [51] [52] [53] [54] [55] [56] . W przeciwieństwie do raka przytarczyc, gruczolak jest zwykle mniejszy, o bardziej miękkiej konsystencji, jajowatego kształtu, zabarwiony na brązowo z odcieniami koloru żółtego [6, 20] (tab. I).
Leczenie operacyjne
W chwili obecnej brak jest jasno określonego systemu klasyfikacji TNM dla raka przytarczyc [10] . Jedyną skuteczną metodą prowadzącą do wyleczenia, nawet w chorobie przerzutowej, nadal jest leczenie operacyjne [2, 3, 5] . Resekcja en bloc obejmująca guz wraz z lobektomią płata tarczycy po tej samej stronie, usunięcie przylegających mięśni oraz przytchawiczych węzłów chłonnych (poziom VI) i w niektórych Tabela I. Objawy mogące wskazywać na raka przytarczyc -Współczynnik kobieta:mężczyzna -1:1 -Średni wiek 45-55 lat
• Objawy kliniczne w momencie rozpoznania (przebieg bezobjawowy < 5%)
• Znacznie podwyższone stężenie PTH (> 5-krotnie lub > 500 pg/ml)
• Wysokie stężenie wapnia w surowicy (>14 mg/dl)
• Wysokie stężenie fosfatazy zasadowej w surowicy (> 300 IU/l)
• Podwyższony poziom jednaostek a-i b-hCG
• Zajęcie nerek (kamica nerkowa, wapnica nerkowa, niewydolność nerek)
• Zajęcie szkieletu (bóle kostne i złamania patologiczne, osteitis fibrosa cystica, rozsiana osteopenia, zmiany radiologiczne w czaszce typu "sól i pieprz")
• Ciężkie zapalenie trzustki lub choroba wrzodowa
• Macalna palpacyjnie masa na szyi lub obrzęk szyi
• Przerzuty odległe
• Chrypka i podrażnienie nerwu krtaniowego wstecznego
• Wielkość guza > 3cm
• Struktura wieloguzkowa zmiany
• Lita struktura guza
• Naciekanie otaczających tkanek Rycina 1. Cechy histopatologiczne, które mogą być obecne w raku przytarczyc
